B2B only. For licensed importers and distributors. Tender authorities and healthcare institutions are also served. Not for retail or patient supply.  ·  Compliance statement
Manufacturer profile

China Resources Boya Bio-pharmaceutical Group

A state-owned plasma platform with the longest export record of the three manufacturers we carry — a Türkiye GMP certificate, a Philippines waiver, and IVIG that has already cleared Brazilian customs.

China has roughly thirty companies licensed to fractionate human plasma. Most of them have never exported a vial. Boya is one of the small group that has, and that difference is the only reason this page is worth reading: an export licence history is harder to obtain than a GMP certificate, and much harder to fake.

This page states what can be checked from public records, what we supply from this manufacturer, and what we are not in a position to claim.

The entity, in verifiable terms

Registered entity
China Resources Boya Bio-pharmaceutical Group Co., Ltd. (华润博雅生物制药集团股份有限公司)
Listing
Shenzhen Stock Exchange, ticker 300294 — a public company, so audited filings are available to any buyer who wants to read them
Controlling group
China Resources Group, a central state-owned enterprise. This matters for tenders: group guarantees and parent-company financials are obtainable where a private fractionator could only offer its own balance sheet
Headquarters
Fuzhou, Jiangxi Province
Plasma collection
21 single-donor plasma collection centres. Collection capacity is the ceiling on fractionation output in China — a manufacturer cannot buy plasma on the open market, so the number of licensed centres is the honest measure of what they can supply
Plasma portfolio
10 products across 31 presentations, spanning albumin, immunoglobulin and coagulation factor classes
Patents
146, per the company's own disclosures

The export record

This is the part a buyer should weigh most heavily, because it is the part that cannot be manufactured retroactively.

An NMPA approval number proves a product may be sold in China. It says nothing about whether the manufacturer can satisfy a foreign regulator — the two are separate competencies, and only one of them has a paper trail.

Boya's trail runs as follows. In 2019 the company passed an official GMP audit by Sri Lankan authorities, and in 2019 shipped IVIG to Brazil for the first time; roughly USD 25 million of IVIG followed across 2020–2021. In January 2020 it passed a Turkish GMP audit, and in 2021 was awarded both a Türkiye GMP certificate and a Philippines GMP waiver. In 2026 the rabies immunoglobulin received Philippine GMP certification.

What this means practically: if your market's regulator asks whether the manufacturer has ever been inspected by an authority outside China, the answer is yes, with dates and issuing bodies you can name. That is a materially different starting position from a supplier whose only inspection record is domestic.

What we supply from Boya

Seven products, each on its own page with the approval number, presentations, storage conditions and document set we can release before a purchase order:

See all seventeen products across three manufacturers →

How to verify any of this yourself

Nothing on this page needs to be taken on trust. Three checks cover most of it:

  • The approval number. Every NMPA drug approval number can be looked up in the national database by the buyer. How to read a Chinese drug approval number explains the format and what each segment asserts.
  • The batch release certificate. For plasma products this is issued by a designated national institute, not by the manufacturer — the manufacturer cannot release a batch on its own authority. What batch release actually gates covers the process.
  • The entity itself. As an SZSE-listed company, Boya files annual and interim reports. Ticker 300294 in any public filing database will give you revenue, production volume and the collection-centre count, independently of anything we or the manufacturer say.

What this page does not claim

We are an authorised export partner, not the manufacturer. Every commercial term — availability, lead time, price, whether a given presentation is in production this quarter — is subject to the manufacturer's confirmation, not ours. Registration status differs by market and is stated per product, not per manufacturer.

Nothing here is a claim about efficacy or safety, and nothing here is directed at patients. Product names and approval numbers remain the property of their holders.